Skip to main content

Preclinical cancer target validation: how not to be wrong

Wednesday, January 24, 2018 - 3:00pm to 4:00pm


William G. Kaelin Jr., M.D.
Dana-Farber Cancer Institute, Harvard Medical School


A Howard Hughes Medical Investigator since 1998, Dr. Kaelin's research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes cause cancer. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of tumor suppressor proteins. His work on the VHL protein helped to motivate the eventual successful clinical testing of VEGF inhibitors for the treatment of kidney cancer. Moreover, this line of investigation led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as anemia, myocardial infarction and stroke.

The page was last updated on Monday, January 22, 2018 - 10:43am